{"id":12592,"date":"2023-07-19T06:57:53","date_gmt":"2023-07-19T06:57:53","guid":{"rendered":"https:\/\/www.wockhardt.com\/about-us\/products\/russia-cis-2\/"},"modified":"2024-09-12T06:13:31","modified_gmt":"2024-09-12T06:13:31","slug":"emerging-markets","status":"publish","type":"page","link":"https:\/\/www.wockhardt.com\/about-us\/products\/emerging-markets\/","title":{"rendered":"Emerging Markets"},"content":{"rendered":"\t\t
\n\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t

Emerging Markets<\/h1>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Sr. No.<\/th>\nProduct Name<\/th>\nGeneric Name<\/th>\nCountry<\/th>\nStrength<\/th>\nTherapy<\/th>\nPack Size<\/th>\n<\/tr>\n<\/thead>\n
1<\/td>\nAZIWOK-500<\/td>\nAzithromycin Tablets USP 500mg<\/td>\nKenya<\/td>\nEach film coated tablet contains:\nAzithromycin USP 500 mg\nExcipients…. Q.S.<\/td>\n\n
    \n \t
  1. macrolide antibiotics\nAzithromycin is an azalide, a sub-class of the macrolid antibiotics. By binding to the 50S-ribosomal sub-unit, azithromycin avoids the translocation of peptide chains from<\/li>\n<\/ol>\none side of the ribosome to the other. As a consequence of this, RNA-dependent protein synthesis in sensitive organisms is prevented<\/td>\n
10 strips of 5 tablets in each enclosed in carton box<\/td>\n<\/tr>\n
2<\/td>\nAZIWOK-250<\/td>\nAzithromycin Tablets USP 250mg<\/td>\nKenya<\/td>\nAzithromycin dihydrate USP\nEquivalent to Azithromycin 250 mg<\/td>\n\n
    \n \t
  1. macrolide antibiotics<\/li>\n \t
  2. Azithromycin is an azalide, a sub-class of the macrolide antibiotics. By binding to the 50S-ribosomal sub-unit, azithromycin avoids the translocation of peptide chains from<\/li>\n<\/ol>\none side of the ribosome to the other. As a consequence of this, RNA-dependent protein synthesis in sensitive organisms is prevented<\/td>\n
11 strips of 5 tablets in each enclosed in carton box<\/td>\n<\/tr>\n
3<\/td>\nBro-Zedex cough syrup<\/td>\nTerbutaline Sulphate Bromhexine HCl Guaifenesin Menthol BP<\/td>\nKenya, Myanmar, Uganda<\/td>\nEach 10 ml contains\nTerbutaline Sulphate BP 2.5 mg\nBromhexine HCL BP 8 mg\nGuaifenesin BP 100.0 mg\nMenthol 5 mg<\/td>\n\n
    \n \t
  1. Cough suppressants, expectorants, mucolytic, and natural remedies<\/li>\n \t
  2. Bro-zedex dilates the airways so as to produce easier breathing and decreases the initiation of reflex<\/li>\n<\/ol>\nIt increase ciliary activity of the respiratory tract fluid<\/td>\n
100 ml clear PET bottle<\/td>\n<\/tr>\n
4<\/td>\nGLARITUS<\/td>\nInsulin Glargine 100IU\/ML<\/td>\nAlgeria, Malaysia, Myanmar, Indonesia, Kenya, Nepal, Philippines, Rwanda ,Vietnam , Uganda, Thailand, Tanzania<\/td>\nEach DispoPen contains : One 3 mL cartridge of Insulin Glargine Injection U.S.P. 100 IU\/mL\nEach ml contains:\nInsulin Glargine U.S.P. …..100 IU\nm-Cresol U.S.P. ……… 0.27% w\/v\n(as preservative)\nWater for Injection U.S.P ….. q.s.<\/td>\nGlaritus 100IU\/ml Injection is a man-made form of insulin that helps to control high blood glucose (sugar) levels. It replaces the insulin that is normally produced in the body. This helps the glucose get into your cells so your body can use it for energy. Lowering of blood sugar level helps reduce the risk of getting any of the serious complications of diabetes such as kidney damage, eye damage, nerve problems, and loss of limbs.<\/td>\n10mL vial, 3mL Cartridge with Dispopen<\/td>\n<\/tr>\n
5<\/td>\nGlutafizz<\/td>\nVitamin C 1000mg, L-Glutathione 500mg<\/td>\nNepal<\/td>\nEach serving contains\nVitamin C* 1000 mg\nL-Glutathione (Reduced) 500 mg<\/td>\nVitamin C with L-Glutathione for a bright and glowy skin with anti ageing properties<\/td>\n15 packets per box<\/td>\n<\/tr>\n
6<\/td>\nGut2Go<\/td>\nWheat Dextrin, Partially hydrolysed Gaur Gum<\/td>\nNepal<\/td>\nEach serving Contains\nWheat Dextrin + 4g\nPartially Hydrolysed Guar Gum 1g<\/td>\nPrebiotic Fiber Supplement\nGut2Go can be consumed just once a day to boost your Fiber intake. It is the convenient way to add Fiber to any beverage or food #.\nThis Synergy Blend may help to:\n
    \n \t
  1. Grow good bacteria in the gut which boost good digestion ^<\/li>\n \t
  2. Lower your cholesterol levels ^ x<\/li>\n \t
  3. Maintain blood sugar levels as an element of healthy diet ^ \u221e<\/li>\n \t
  4. Feel Fuller ^<\/li>\n<\/ol>\n<\/td>\n
100 gm jar<\/td>\n<\/tr>\n
7<\/td>\nHeparin Sodium Injection USP 25000IU\/5ml<\/td>\nHeparin Sodium Injection USP 25000IU\/5ml<\/td>\nKenya<\/td>\nCOMPOSITION\nEach ml contains:\nHeparin Sodium USP 1000 IU \/ 5000 IU\nBenzyl Alcohol USP 1.5% v\/v\nWater For Injection USP q.s.<\/td>\nHeparin is a heterogeneous group of straight-chain anionic mucopolysaccharides, called glycosaminoglycan’s, possessing anticoagulant properties. It is composed of polymers of alternating derivations of \u03b1-D-glucosamido (N-sulphated O-sulphated or Nacetylated) and O-sulphated uronic acid (\u03b1-L-iduronic acid or \u03b2-D-glucuronic acid).<\/td>\n5 ml Vial<\/td>\n<\/tr>\n
8<\/td>\nKefstar 750 mg Injection<\/td>\nCefuroxime Axetil 750mg USP<\/td>\nKenya<\/td>\nEach vial contains : Sterile Cefuroxime Sodium USP equivalent to Cefuroxime 750 mg\nB) One disposable sterile syringe and needle and One ampoule containing 10 ml of Sterilised\nWater for Injections B.P<\/td>\nKEFSTAR (Cefuroxime Sodium) is a semi-synthetic, broad-spectrum cephalosporin antibiotic for injectable use. Cefuroxime is usually bactericidal in action. Its action results from the inhibition of\nmucopeptide synthesis in the bacterial cell wall<\/td>\n750 mg in a vial<\/td>\n<\/tr>\n
9<\/td>\nKefstar-500 tablets<\/td>\nCefuroxime Axetil 500mg USP<\/td>\nKenya<\/td>\nEach film coated tablet contains:\nCefuroxime Axetil USP equivalent to anhydrous\nCefuroxime……………………………….500 mg<\/td>\nCefuroxime is indicated for the treatment of the following infections:\nPharyngitis and tonsillitis caused by S. pyogenes (group A beta-haemolytic strepto cocci). Otitis media (acute bacterial) caused by S. pneumoniae, H. influenza (beta-lactamase producing strains), M. catarrhalis (beta lactamase- producing strains) and S. pyogenes\nAcute bacterial maxillary sinusitis caused by S. pneumoniae or H.\ninfluenzas (non-beta-lactamase-producing strains only)\nAcute bacterial exacerbations of chronic bronchitis and secondary\nbacterial infections of acute bronchitis caused by S. pneumoniae, H.\ninfluenzas (beta-lactamase-negative strains) or H. parainfluenzae (beta lactamase- negative strains)<\/td>\n10 Tablets per strip<\/td>\n<\/tr>\n
10<\/td>\nMANIX HERBAL CAPSULES<\/td>\n<\/td>\nKenya<\/td>\nEach MANIX capsule contains:\nAsparagus racemosus (Shatavari) Extract 42.0 mg\nCinnamomum tamala (Tamalpatra) Powder 16.5 mg\nCinnamomum zeylanicum (Dalchini) Powder 16.5 mg\nDioscorea bulbifera (Varahikand) Powder 207.0 mg\nElettaria cardamomum (Elaichi) Powder 16.5 mg\nPlumbago zeylanica (Chitrak) Extract 85.0 mg\nPueraria tuberosa (Vidarikand) Extract 10 mg\nSemecarpus anacardium (Godambi) Extract 45.0 mg\nSesamum indicum (Kalatil) Powder 99.0 mg\nTinospora cordifolia (Guduchi) Extract 40.0 mg\nTribulus terrestris (Gokshru) Extract 45.0 mg\nSodium Benzoate BP 0.2% w\/w<\/td>\nMANIX capsule is a polyherbal formulation of indigenous medicinal herbs. The combination contain various phytochemicals like essential oils, glycosides, saponins, isoflavones, biflavones, alkaloids, lactones, steroids, phenolics, aliphatic compounds and polysaccharides as the active components. MANIX is a clinically proven combination of\nthe unique herbal ingredients in the treatment of male sexual disorders<\/td>\n10 Capsules per strip<\/td>\n<\/tr>\n
11<\/td>\nMerimix<\/td>\nMeropenem Trihydrate<\/td>\nTanzania<\/td>\nMeropenem USP (as trihydrate)\nEquivalent to anhydrous Meropenem\u2026\u2026.1000 mg\nSodium (as sodium carbonate IP)\u2026\u2026\u2026\u202690.2 mg\nSulbactam Sodium USP\nEquivalent to Sulbactam\u2026\u2026\u2026\u2026\u2026\u2026\u2026..500 mg<\/td>\nMeropenem\/Sulbactam for Injection I.V. is useful as presumptive therapy in the indicated condition (e.g., intraabdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity<\/td>\n1 gm vial<\/td>\n<\/tr>\n
12<\/td>\nMYPEN<\/td>\nINSULIN DELIVERY DEVICE<\/td>\nSrilanka<\/td>\nINSULIN DELIVERY DEVICE<\/td>\nIt is an innovative insulin pen designed for precise and convenient insulin delivery. This pen is suitable for individuals with diabetes who require insulin therapy to manage their blood sugar levels.<\/td>\n1 unit\/box<\/td>\n<\/tr>\n
13<\/td>\nNADIMIX CREAM<\/td>\nNADIFLOXACIN, MICONAZOLE NITRATE, MOMETASONE FUROATE<\/td>\nKenya, Myanmar<\/td>\nEach gm contains\nNadifloxacin ……………………… 10 mg\nMiconazole Nitrate BP ……….. 20 mg\nMometasone Furoate USP .. 01 mg<\/td>\nNadofloxacin is systemic quinolone with potent broad spectrum antibacterial activity . Miconazole is a potent imidazole antifungal with a broad anti fungal spectrum . Mometasone furoate a moderately potent coticosteroids has been shown to have topical systemic pharmacological and metabolic effects characteristics of this class of drugs<\/td>\nLaminated tube of 7.5g in a carton box<\/td>\n<\/tr>\n
14<\/td>\nNadoxin Cream<\/td>\nNadifloxacin 10mg\/g<\/td>\nKenya, Myanmar, Uganda, Tanzania<\/td>\nEach gram of cream contains\nNadifloxacin 10 mg\nIn a cream base q.s.<\/td>\nNadoxin is synthetic quinolone with potent broad spectrum antibacterial activity . It is intended for the treatment of acne vulgaris caused by propionibacterium acnes and staphylococcus spp. Prominent efficacy , low potential in including resistance in microorganism and high acterial activity against drug resistant microorgannism<\/td>\n10 g Laminated tube in a carton box<\/td>\n<\/tr>\n
15<\/td>\nNuroday tablet<\/td>\nMecobalamin JP 1500mcg\/ extended release tablet<\/td>\nMyanmar<\/td>\nComposition\nEach Extended Release tablet contains:\nMecobalamin JP ….. 1500 mcg<\/td>\nMan-made form of Vitamin B12 which is important for nerve health, brain function, and red blood cell production. This medicine is mainly used to treat Vitamin B12 deficiency in people with anaemia and peripheral neuropathy (nerve pain in hands and feet)<\/td>\nAlu-Alu blister pack of 1 x 10’s in a monocarton such 10 monocartons in a box<\/td>\n<\/tr>\n
16<\/td>\nPHYTON 2.25g<\/td>\nPiperacillin and Tazobactam for injection USP<\/td>\nKenya, Zambia<\/td>\nEach vial contains:\nSterile Piperacillin Sodium USP\nEquivalent to Piperacillin……2.0g\nSterile Tazobactam Sodium\nEquivalent to Tazobactam……0.25g\nSodium .4.46mEq (102.5 mg)<\/td>\nSevere pneumonia including hospital-acquired and ventilator-associated pneumonia\nComplicated urinary tract infections (including pyelonephritis)\n– Complicated intra-abdominal infections\n– Complicated skin and soft tissue infections (including diabetic foot infections)\n-Treatment of patients with bacteraemia that occurs in association with, or is\nsuspected to be associated with, any of the infections listed above.\n– Piperacillin\/Tazobactam may be used in the management of neutropenic patients\nwith fever suspected to be due to a bacterial infection.<\/td>\n2 ml vial<\/td>\n<\/tr>\n
17<\/td>\nPHYTON 4.5g<\/td>\nPiperacillin and Tazobactam for injection USP<\/td>\nKenya, Zambia<\/td>\nSterile Piperacillin Sodium USP equivalent to Piperacillin \u2026\u2026\u2026\u2026\u2026.\u20264.0 G\nTazobactam Sodium equivalent to Tazobactam\u2026\u2026\u2026\u2026\u2026\u2026.0.5 G\nSodium 8.9meq (205mg)<\/td>\nSevere pneumonia including hospital-acquired and ventilator-associated pneumonia\n-Complicated urinary tract infections (including pyelonephritis)\n– Complicated intra-abdominal infections – Complicated skin and soft tissue infections (including diabetic foot infections)\n-Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.\n– Piperacillin\/Tazobactam may be used in the management of neutropenic patients with fever suspected to be due to a bacterial infection<\/td>\n3 ml vial<\/td>\n<\/tr>\n
18<\/td>\nPowercef Injection 1 gm<\/td>\nCeftriaxone Sodium 1 gm<\/td>\nKenya, Myanmar, Uganda, Tanzania<\/td>\nEach vial contains:\nSterile Ceftriaxone Sodium USP\nequivalent to anhydrous\nCeftriaxone …………………….. 1 g<\/td>\nPOWERCEF is a sterile, semisynthetic, broad-spectrum\ncephalosporin antibiotic for intravenous or intramuscular\nadministration. The bactericidal activity of Ceftriaxone results form the inhibition of cell wall synthesis. Ceftriaxone demonstrates a high degree of stability in the presence of Blactamases both penicillinases and cephalosporins of gram-negative and gram-positive bacteria. Ceftriaxone is usually active against following micro-organisms invitro.<\/td>\n2 ml flint glass vial in a carton box<\/td>\n<\/tr>\n
19<\/td>\nWepox 2000<\/td>\nRecombinant Human Erythropoetin Injection 2000 IU<\/td>\nSrilanka, Tanzania, Uganda<\/td>\nEach 0.5 ml contains :\nRecombinant Human Erythropoietin 2000 IU<\/td>\nTreatment of anaemia due to erythropoietin deficiency in adult chronic renal failure patients and in\npredialysis, haemodialysis, peritoneal dialysis patients and in paediatric patients on haemodialysis.\nTreatment of anaemia in cancer patients with non-myeloid malignancies (with or without chemotherapy) and prevention of anemia in cancer patients with non-myeloid malignancies who\nare undergoing chemotherapy treatment.\nTreatment of anaemia in HIV-infected patients on zidovudine with endogenous erythropoietin levels \u2264500 mU\/ml.<\/td>\nSingle dose. USP Type I Pre-filled Glass Syringe\n(Box of 1’s)<\/td>\n<\/tr>\n
20<\/td>\nWepox 4000<\/td>\nRecombinant Human Erythropoetin Injection 4000 IU<\/td>\nSrilanka, Tanzania, Uganda<\/td>\nEach 0.4 ml contains :\nRecombinant Human Erythropoietin 4000 IU<\/td>\nTreatment of anaemia due to erythropoietin deficiency in adult chronic renal failure patients and in predialysis, haemodialysis, peritoneal dialysis patients and in paediatric patients on haemodialysis. Treatment of anemia in cancer patients with non-myeloid malignancies (with or without chemotherapy) and prevention of anemia in cancer patients with non-myeloid malignancies who\nare undergoing chemotherapy.\nTreatment of anemia in HIV-infected patients on zidovudine with endogenous erythropoietin levels \u2264500 mU\/ml.\nTo aid autologous blood collection in patients scheduled for elective surgery, with hematocrits of 33- 39%, who cannot produce the required blood without exogenous erythropoietin.<\/td>\nSingle dose. USP Type I Pre-filled Glass Syringe\n(Box of 1’s)<\/td>\n<\/tr>\n
21<\/td>\nWepox 5000<\/td>\nRecombinant Human Erythropoetin Injection 5000 IU<\/td>\nSrilanka, Tanzania, Uganda<\/td>\nEach 0.5 ml contains :\nRecombinant Human Erythropoietin 5000 IU<\/td>\nWEPOX is indicated for the treatment of symptomatic anaemia associated with chronic\nrenal failure (CRF):\n
    \n \t
  • In adults and paediatrics aged 1 to 18 years on haemodialysis and adult patients on\nperitoneal dialysis.<\/li>\n \t
  • In adults with renal insufficiency not yet undergoing dialysis for the treatment of\nsevere anaemia of renal origin accompanied by clinical symptoms in patients.<\/li>\n<\/ul>\n<\/td>\n
Single dose. USP Type I Pre-filled Glass Syringe\n(Box of 1’s)<\/td>\n<\/tr>\n
22<\/td>\nWepox 10000<\/td>\nRecombinant Human Erythropoetin Injection 10000 IU<\/td>\nSrilanka, Tanzania, Uganda<\/td>\nEach 1 ml contains :\nRecombinant Human Erythropoietin 10000 IU<\/td>\nThis medicine is primarily indicated for treating anemia (low red blood cell count) in persons with long-term serious (chronic) kidney disease, persons receiving chemotherapy for some types of cancer except for bone marrow or blood cells cancer, and persons taking zidovudine to treat HIV(human immunodeficiency virus).<\/td>\nSingle dose. USP Type I Pre-filled Glass Syringe\n(Box of 1’s)<\/td>\n<\/tr>\n
23<\/td>\nWepox 30000<\/td>\nRecombinant Human Erythropoetin Injection 30000 IU<\/td>\nSrilanka, Tanzania, Uganda<\/td>\nEach Cartridge (3.0 ml) for pen contains:\nRecombinant Human Erythropoietin Ph. Eur. 30000 IU<\/td>\nWEPOX is indicated for the treatment of symptomatic anaemia associated with chronic renal\nfailure (CRF):\n
    \n \t
  • In adults and paediatrics aged 1 to 18 years on haemodialysis and adult patients on peritoneal\ndialysis.<\/li>\n \t
  • In adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients.<\/li>\n<\/ul>\nWEPOX is indicated in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient’s general status (e.g.\ncardiovascular status, pre-existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements.<\/td>\n
Single dose. USP Type I Pre-filled Glass Syringe\n(Box of 1’s)<\/td>\n<\/tr>\n
24<\/td>\nWosulin N<\/td>\nInsulin Injection, Isophane 100 IU<\/td>\nMozambique, Myanmar, Kenya, Nepal, Philippines, Nigeria, Srilanka, Tanzania, Thailand, Vietnam<\/td>\nEach mL contains\nHuman Insulin IP\/USP\/Ph.Eur 100 IU\nm-Cresol USP\/ Ph.Eur (As preservative) 0.16% w\/v\nPhenol IP\/USP\/Ph.Eur (As preservative) 0.065 w\/v\nWater for Injections IP\/USP\/Ph.Eur Q.S.<\/td>\nIsophane insulin human suspension -N is indicated for the following\n
    \n \t
  1. Treatment of all patient with type 1 diabetes<\/li>\n \t
  2. Treatment of patient with type 2 diabetes who are not adequately controlled by diet and oral hypoglycemic agents<\/li>\n \t
  3. Treatment of gestational diabetes<\/li>\n \t
  4. For initial stabilization of diabetes in patient with diabetic ketoacidosis , hypersmolar non ketotic syndrome and during periods of stress such as severe infection and major surgery in diabetic patients.<\/li>\n<\/ol>\n<\/td>\n
10 ml filled in a glass vial with bromobutyl plug and flip off seal. 1 vial packed in a printed carton with literature insert, and 3 mL filled in a glass cartridge. 1 cartridge blister packed in a printed carton with literature insert.<\/td>\n<\/tr>\n
25<\/td>\nWosulin R<\/td>\nInsulin Injection, Soluble 100 IU<\/td>\nMozambique, Myanmar, Kenya, Nepal, Philippines, Nigeria, Srilanka, Tanzania, Thailand, Vietnam<\/td>\nEach mL contains\nHuman Insulin IP\/USP\/Ph.Eur 100 IU\nm-Cresol USP\/ Ph.Eur (As preservative) 0.25% w\/v\nWater for Injections IP\/USP\/Ph.Eur Q.S.<\/td>\nInsulin human regular is indicated for the following\n
    \n \t
  1. Treatment of all patient with type 1 diabetes<\/li>\n \t
  2. Treatment of patient with type 2 diabetes who are not adequately controlled by diet and oral hypoglycemic agents<\/li>\n \t
  3. Treatment of gestational diabetes<\/li>\n \t
  4. For initial stabilization of diabetes in patient with diabetic ketoacidosis , hypersmolar non ketotic syndrome and during periods of stress such as severe infection and major surgery in diabetic patients.<\/li>\n<\/ol>\n<\/td>\n
10 ml filled in a glass vial with bromobutyl plug and flip off seal. 1 vial packed in a printed carton with literature insert, and 3 mL filled in a glass cartridge. 1 cartridge blister packed in a printed carton with literature insert.<\/td>\n<\/tr>\n
26<\/td>\nWosulin 30\/70<\/td>\nInsulin Injection, Biphasic Isophane 100 IU<\/td>\nMozambique, Myanmar, Kenya, Nepal, Philippines, Nigeria, Srilanka, Tanzania, Thailand, Vietnam<\/td>\nEach mL contains:\nInsulin Human USP 100 IU (30% Regular Insulin Human neutral and 70% Isophane Insulin)\nm-Cresol USP 0.16% w\/v as preservative\nPhenol USP 0.065 w\/v as preservative\nWater for Injection USP q.s.<\/td>\nWOSULIN-30\/70 is indicated for the following:\n
    \n \t
  • Treatment of all patients with type 1 diabetes<\/li>\n \t
  • Treatment of patients with type 2 diabetes who are not adequately controlled by diet and \/ or oral hypoglycemic agents.<\/li>\n \t
  • For the initial stabilization of diabetes in patients with diabetic ketoacidosis, hyperosmolar non-ketotic syndrome and during periods of stress such as severe infections and major surgery in diabetic patients.<\/li>\n \t
  • Treatment of Gestational diabetes.<\/li>\n<\/ul>\n<\/td>\n
10 ml filled in a glass vial with bromobutyl plug and flip off seal. 1 vial packed in a printed carton with literature insert, and 3 mL filled in a glass cartridge. 1 cartridge blister packed in a printed carton with literature insert.<\/td>\n<\/tr>\n
27<\/td>\nWosulin N<\/td>\nInsulin Injection, Isophane 40 IU<\/td>\nNepal<\/td>\nEach ml of Insulin isophane contains\nHuman insulin USP 40 IU\nm-cresol USP \u2013 preservative 0.16% w\/w\nPhenol USP \u2013 preservative 0.065% w\/w\nwater for injection USP<\/td>\nWosulin-N 40IU\/ml Suspension for Injection is an intermediate-acting type of insulin that is usually used along with other diabetes medication for controlling blood sugar levels. It replaces the insulin that is normally produced in the body. This helps the glucose get into your muscle and fat cells so your body can use it for energy. It also decreases glucose production in the liver.<\/td>\n10 ml filled in a glass vial with bromobutyl plug and flip off seal. 1 vial packed in a printed carton with literature insert.<\/td>\n<\/tr>\n
28<\/td>\nWosulin R<\/td>\nInsulin Injection, Soluble 40 IU<\/td>\nNepal<\/td>\nEach ml contains\nHuman insulin USP 40 IU\nm-cresol USP \u2013 preservative 0.25% w\/w\nwater for injection USP<\/td>\nTreatment of all patients with type 1 diabetes\n
    \n \t
  • Treatment of patients with type 2 diabetes who are not adequately controlled by diet and \/\nor oral hypoglycemic agents.<\/li>\n \t
  • For the initial stabilization of diabetes in patients with diabetic ketoacidosis, hyperosmolar\nnon-ketotic syndrome and during periods of stress such as severe infections and major\nsurgery in diabetic patients. \n
      Treatment of Gestational diabetes<\/ul>\n<\/li>\n<\/ul>\n<\/td>\n
11 ml filled in a glass vial with bromobutyl plug and flip off seal. 1 vial packed in a printed carton with literature insert.<\/td>\n<\/tr>\n
29<\/td>\nWosulin 30\/70<\/td>\nInsulin Injection, Biphasic Isophane 40 IU<\/td>\nNepal<\/td>\nEach mL contains:\nInsulin Human USP 40IU (30% Regular Insulin Human neutral and 70% Isophane Insulin)\nm-Cresol USP 0.16% w\/v as preservative\nPhenol USP 0.065 w\/v as preservative\nWater for Injection USP q.s.<\/td>\nTreatment of all patients with type 1 diabetes\n
    \n \t
  • Treatment of patients with type 2 diabetes who are not adequately controlled by diet and \/\nor oral hypoglycemic agents.<\/li>\n \t
  • For the initial stabilization of diabetes in patients with diabetic ketoacidosis, hyperosmolar\nnon-ketotic syndrome and during periods of stress such as severe infections and major\nsurgery in diabetic patients.<\/li>\n<\/ul>\nTreatment of Gestational diabetes<\/td>\n
12 ml filled in a glass vial with bromobutyl plug and flip off seal. 1 vial packed in a printed carton with literature insert.<\/td>\n<\/tr>\n
30<\/td>\nWokadine solution<\/td>\nPovidone Iodine solution 10 % w\/v<\/td>\nKenya<\/td>\nPovidone-Iodine USP 10% w\/v (Available Iodine 1% w\/v)<\/td>\nGeneral Surgery: For peritoneal lavage in peritonitis to decontaminate\nperitoneal cavity. For irrigation of operative wounds before closure, especially\nafter abdominal operations.\n
    \n \t
  • Plastic Surgery: For decontamination of traumatic wounds. For preoperative\npreparation of area before skin grafting.<\/li>\n \t
  • Urosurgery: Preoperative urinary bladder instillation in the course of transurethral\noperations. During routine catheterisation to prevent postcatheterisation infection rate.<\/li>\n \t
  • Colo-rectal Surgery: For preoperative colonic wash for decontamination of colon. Intraoperative wash of the affected segment for regional antisepsis.<\/li>\n \t
  • Orthopaedic Surgery: For painting the affected limb prior to immobilizing it in a plaster of paris cast. For washing osteomyletic cavity<\/li>\n<\/ul>\n<\/td>\n
100 ml bottle in carton box<\/td>\n<\/tr>\n
31<\/td>\nWokadine Spray<\/td>\nPovidone Iodine Spray 0.45% w\/v<\/td>\nKenya<\/td>\nPovidone-Iodine USP 0.45% w\/v (Available iodine 0.045 % w\/v)<\/td>\nPovidone-Iodine Sore Throat Spray is indicated for the symptomatic relief of painful, irritated sore throats. It is effective against bacteria, fungi, yeasts and protozoa. It is used as an antiseptic treatment in the throat. It is non-irritating and non-stinging to skin and mucosa.<\/td>\n100 ml and 50 ml bottle in a carton box<\/td>\n<\/tr>\n
32<\/td>\nWokadine Ointment<\/td>\nPovidone Iodine 10% w\/v ointment<\/td>\nKenya<\/td>\nPovidone-Iodine USP 10% w\/w (Available Iodine 1% w\/w)<\/td>\nFor the topical treatment or prevention of infection in minor cuts and abrasions, minor surgical procedures and small\nareas of burns.\n
    \n \t
  • Treatment of mycotic and bacterial skin infections and pyoderma.<\/li>\n \t
  • Treatment of infections in decubitus and stasis ulcers.<\/li>\n \t
  • Degerming skin in hyperalimentation and catheter care.<\/li>\n<\/ul>\n<\/td>\n
Laminated tube of 15g in a carton box (ointment)<\/td>\n<\/tr>\n
33<\/td>\nWokadine Gargle<\/td>\nPovidone Iodine Gargle 1% w\/v<\/td>\nKenya<\/td>\nPovidone Iodine USP 1 % w\/v (Available Iodine 0.1 % w\/v)\nAbsolute Alcohol 8.38 % v\/v in a specially denatured vehicle\nIn a mint flavoured base q.s.<\/td>\nFor inflammatory conditions of the mouth and pharynx caused by bacterial or monilial infections including pharyngitis, tonsillitis, aphthous ulcers, stomatitis, gingivitis,glossitis, secondary infected traumatic or herpetic ulcers\n
    \n \t
  • In dental surgery and oral operative procedures.<\/li>\n \t
  • In pericoronitis.<\/li>\n \t
  • IAs a prophylactic mouthwash.<\/li>\n \t
  • To deodorize and refresh the mouth in febrile, post-operative or bed-ridden<\/li>\n<\/ul>\npatients and others who require the promotion of oral hygiene<\/td>\n
100 ml bottle in carton box<\/td>\n<\/tr>\n
34<\/td>\nWokadine Scrub<\/td>\nPovidone Iodine Scrub<\/td>\nKenya<\/td>\nPovidone-Iodine USP 7.5% w\/v\n(Available Iodine 0.75% w\/v)\nNon-ionic Detergent base q.s.<\/td>\nBroad spectrum topical microbicidal effective against\nbacteria, fungi, protozoa, yeasts and viruses<\/td>\n500 ml bottle (Scrub)<\/td>\n<\/tr>\n
35<\/td>\nZEDEX D capsule<\/td>\nACETAMINOPHEN 325MG, DEXTROMETHORPHAN HYDROBROMIDE 10MG,DOXYLAMINE SUCCINATE 6.25MG<\/td>\nUganda<\/td>\nComposition\nEach Soft Gelatin Capsule Contains:\nAcetaminophen USP 325 mg\nDextromethorphan Hydrobromide USP 10 mg\nDoxylamine Succinate USP 6.25 mg\nExcipients q.s.<\/td>\nFor temporary relief in common cold and flu symptoms like minor aches and pains, headache, sore throat, fever, sneezing, runny\nnose and cough due to minor throat and bronchial irritation.<\/td>\n1 pack of 10 capsules<\/td>\n<\/tr>\n
36<\/td>\nZEDEX<\/td>\nBromhexine Hydrochloride BP Dextromethorphan Hydrobromide BP<\/td>\nKENYA<\/td>\nEach 10 ml contains\nBromhexine Hydrochloride BP 8 mg\nDextromethorphan Hydrobromide BP 10 mg\nAmmonium Chloride BP 100 mg\nMenthol BP 5 mg\nFlavoured sryupy base q.s\nColours : Briliant blue FCF and Tartrazine<\/td>\nFor the symptomatic treatment of irritating and hacking cough, cough associated with URTI, bronchitis, pulmonary congestion where retention of tenacious and viscid mucoid secretion is a problem.<\/td>\n100 ml clear PET bottle in a carton box<\/td>\n<\/tr>\n
37<\/td>\nZEDEX COLD capsule<\/td>\nACETAMINOPHEN 325MG, DEXTROMETHORPHAN HYDROBROMIDE 10MG,DOXYLAMINE SUCCINATE 6.25MG<\/td>\nNigeria , uganda<\/td>\nEach Soft Gelatin Capsule Contains:\nAcetaminophen USP 325 mg\nDextromethorphan Hydrobromide USP 10 mg\nPhenylephrine Hydrochloride USP 5 mg\nExcipients q.s.<\/td>\nFor temporary relief in common cold and flu symptoms like minor aches and pains, headache, sore throat, fever, nasal\ncongestion and cough due to minor throat and bronchial irritation.<\/td>\n1 pack of 10 capsules<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Emerging Markets Sr. No. Product Name Generic Name Country Strength Therapy Pack Size 1 AZIWOK-500 Azithromycin Tablets USP 500mg Kenya Each film coated tablet contains: Azithromycin USP 500 mg Excipients…. Q.S. macrolide antibiotics Azithromycin is an azalide, a sub-class of the macrolid antibiotics. By binding to the 50S-ribosomal sub-unit, azithromycin avoids the translocation of peptide … <\/p>\n

Continue reading “Emerging Markets”<\/span><\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"parent":10430,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"yoast_head":"\nEmerging Markets - Wockhardt<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.wockhardt.com\/about-us\/products\/emerging-markets\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emerging Markets - Wockhardt\" \/>\n<meta property=\"og:description\" content=\"Emerging Markets Sr. No. Product Name Generic Name Country Strength Therapy Pack Size 1 AZIWOK-500 Azithromycin Tablets USP 500mg Kenya Each film coated tablet contains: Azithromycin USP 500 mg Excipients…. Q.S. macrolide antibiotics Azithromycin is an azalide, a sub-class of the macrolid antibiotics. By binding to the 50S-ribosomal sub-unit, azithromycin avoids the translocation of peptide … Continue reading "Emerging Markets"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.wockhardt.com\/about-us\/products\/emerging-markets\/\" \/>\n<meta property=\"og:site_name\" content=\"Wockhardt\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-12T06:13:31+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"17 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.wockhardt.com\/about-us\/products\/emerging-markets\/\",\"url\":\"https:\/\/www.wockhardt.com\/about-us\/products\/emerging-markets\/\",\"name\":\"Emerging Markets - Wockhardt\",\"isPartOf\":{\"@id\":\"https:\/\/www.wockhardt.com\/#website\"},\"datePublished\":\"2023-07-19T06:57:53+00:00\",\"dateModified\":\"2024-09-12T06:13:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.wockhardt.com\/about-us\/products\/emerging-markets\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.wockhardt.com\/about-us\/products\/emerging-markets\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.wockhardt.com\/about-us\/products\/emerging-markets\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.wockhardt.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"About Us\",\"item\":\"https:\/\/www.wockhardt.com\/about-us\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"products\",\"item\":\"https:\/\/www.wockhardt.com\/about-us\/products\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Emerging Markets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.wockhardt.com\/#website\",\"url\":\"https:\/\/www.wockhardt.com\/\",\"name\":\"Wockhardt\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.wockhardt.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.wockhardt.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.wockhardt.com\/#organization\",\"name\":\"Wockhardt\",\"url\":\"https:\/\/www.wockhardt.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.wockhardt.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.wockhardt.com\/wp-content\/uploads\/2022\/09\/Wockhardt-logo_Golden-50-years_20_07_17-1.png\",\"contentUrl\":\"https:\/\/www.wockhardt.com\/wp-content\/uploads\/2022\/09\/Wockhardt-logo_Golden-50-years_20_07_17-1.png\",\"width\":256,\"height\":70,\"caption\":\"Wockhardt\"},\"image\":{\"@id\":\"https:\/\/www.wockhardt.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Emerging Markets - Wockhardt","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.wockhardt.com\/about-us\/products\/emerging-markets\/","og_locale":"en_US","og_type":"article","og_title":"Emerging Markets - Wockhardt","og_description":"Emerging Markets Sr. No. Product Name Generic Name Country Strength Therapy Pack Size 1 AZIWOK-500 Azithromycin Tablets USP 500mg Kenya Each film coated tablet contains: Azithromycin USP 500 mg Excipients…. Q.S. macrolide antibiotics Azithromycin is an azalide, a sub-class of the macrolid antibiotics. By binding to the 50S-ribosomal sub-unit, azithromycin avoids the translocation of peptide … Continue reading \"Emerging Markets\"","og_url":"https:\/\/www.wockhardt.com\/about-us\/products\/emerging-markets\/","og_site_name":"Wockhardt","article_modified_time":"2024-09-12T06:13:31+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"17 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.wockhardt.com\/about-us\/products\/emerging-markets\/","url":"https:\/\/www.wockhardt.com\/about-us\/products\/emerging-markets\/","name":"Emerging Markets - Wockhardt","isPartOf":{"@id":"https:\/\/www.wockhardt.com\/#website"},"datePublished":"2023-07-19T06:57:53+00:00","dateModified":"2024-09-12T06:13:31+00:00","breadcrumb":{"@id":"https:\/\/www.wockhardt.com\/about-us\/products\/emerging-markets\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.wockhardt.com\/about-us\/products\/emerging-markets\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.wockhardt.com\/about-us\/products\/emerging-markets\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.wockhardt.com\/"},{"@type":"ListItem","position":2,"name":"About Us","item":"https:\/\/www.wockhardt.com\/about-us\/"},{"@type":"ListItem","position":3,"name":"products","item":"https:\/\/www.wockhardt.com\/about-us\/products\/"},{"@type":"ListItem","position":4,"name":"Emerging Markets"}]},{"@type":"WebSite","@id":"https:\/\/www.wockhardt.com\/#website","url":"https:\/\/www.wockhardt.com\/","name":"Wockhardt","description":"","publisher":{"@id":"https:\/\/www.wockhardt.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.wockhardt.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.wockhardt.com\/#organization","name":"Wockhardt","url":"https:\/\/www.wockhardt.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.wockhardt.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.wockhardt.com\/wp-content\/uploads\/2022\/09\/Wockhardt-logo_Golden-50-years_20_07_17-1.png","contentUrl":"https:\/\/www.wockhardt.com\/wp-content\/uploads\/2022\/09\/Wockhardt-logo_Golden-50-years_20_07_17-1.png","width":256,"height":70,"caption":"Wockhardt"},"image":{"@id":"https:\/\/www.wockhardt.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.wockhardt.com\/wp-json\/wp\/v2\/pages\/12592"}],"collection":[{"href":"https:\/\/www.wockhardt.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.wockhardt.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.wockhardt.com\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wockhardt.com\/wp-json\/wp\/v2\/comments?post=12592"}],"version-history":[{"count":12,"href":"https:\/\/www.wockhardt.com\/wp-json\/wp\/v2\/pages\/12592\/revisions"}],"predecessor-version":[{"id":12635,"href":"https:\/\/www.wockhardt.com\/wp-json\/wp\/v2\/pages\/12592\/revisions\/12635"}],"up":[{"embeddable":true,"href":"https:\/\/www.wockhardt.com\/wp-json\/wp\/v2\/pages\/10430"}],"wp:attachment":[{"href":"https:\/\/www.wockhardt.com\/wp-json\/wp\/v2\/media?parent=12592"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}